Literature DB >> 14723976

From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid.

C Guin Ting Wong1, K Michael Gibson, O Carter Snead.   

Abstract

gamma-Hydroxybutyric acid (GHB) is a short-chain fatty acid that occurs naturally in the mammalian brain and is formed primarily from the precursor gamma-aminobutyric acid (GABA). The properties of GHB suggest that it has a neuromodulatory role in the brain and has the ability to induce several pharmacological and behavioral effects. GHB has been used clinically as an anesthetic and to treat alcoholism and narcolepsy. Furthermore, GHB has emerged recently as a major recreational drug of abuse. GHB appears to have dual mechanisms of action in the brain. Biochemical data suggest that the intrinsic neurobiological activity of GHB might be mediated through the GHB receptor, which is separate and distinct from the GABA(B) receptor. However, many of the pharmacological and clinical effects of exogenously administered GHB, including the properties of addiction, tolerance, withdrawal and intoxication, are probably mediated via the GABA(B) receptor, where GHB might act both directly as a partial agonist and indirectly through GHB-derived GABA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14723976     DOI: 10.1016/j.tips.2003.11.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  46 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

Review 2.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

Review 3.  Unravelling the brain targets of gamma-hydroxybutyric acid.

Authors:  Vincenzo Crunelli; Zsuzsa Emri; Nathalie Leresche
Journal:  Curr Opin Pharmacol       Date:  2005-12-20       Impact factor: 5.547

4.  Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348).

Authors:  Wouter Koek; Susan L Mercer; Andrew Coop; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2009-06-29       Impact factor: 4.030

5.  γ-Hydroxybutyric acid-induced electrographic seizures.

Authors:  Joseph Cheung; Brendan P Lucey; Stephen P Duntley; Rachel S Darken
Journal:  J Clin Sleep Med       Date:  2014-07-15       Impact factor: 4.062

Review 6.  Alternative drugs of abuse.

Authors:  M E Sutter; J Chenoweth; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

7.  Effects of 1,4-butanediol administration on oxidative stress in rat brain: study of the neurotoxicity of gamma-hydroxybutyric acid in vivo.

Authors:  Angela M Sgaravatti; Alessandra S Magnusson; Amanda S Oliveira; Caroline P Mescka; Fernanda Zanin; Mirian B Sgarbi; Carolina D Pederzolli; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Carlos S Dutra-Filho
Journal:  Metab Brain Dis       Date:  2009-03-19       Impact factor: 3.584

8.  Deletion of phospholipase C beta4 in thalamocortical relay nucleus leads to absence seizures.

Authors:  Eunji Cheong; Yihong Zheng; Kyoobin Lee; Jungryun Lee; Seongwook Kim; Maryam Sanati; Sukyung Lee; Yeon-Soo Kim; Hee-Sup Shin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

9.  Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.

Authors:  Matthias E Liechti; Boris B Quednow; Evangelia Liakoni; Dario Dornbierer; Robin von Rotz; Maria Salomé Gachet; Jürg Gertsch; Erich Seifritz; Oliver G Bosch
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

10.  The drug of abuse gamma-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition.

Authors:  Dapeng Cui; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2009-04-23       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.